Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

325 Press Releases
DateTitleCompany
29 May 15 Teva Enhances Extensive Women’s Health Portfolio with Launch of Generic Lomedia® 24 Fe Tablets Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
15 May 15 Teva to Present New Respiratory Data at 2015 Annual International Meeting of the American Thoracic Society Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
14 May 15 Teva Presents Further Data from Phase IIb with TEV-48125 in Chronic Migraine at the International Headache Society Congress (IHC): Efficacy and Safety Results at All Doses and Endpoints Present Robust Case for Progression to Phase III Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
08 May 15 Teva to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 May 15 Teva Completes Acquisition of Auspex Pharmaceuticals Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 May 15 Teva Provides Additional Detail on Proposed Acquisition of Mylan Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Apr 15 Teva Launches Generic Abilify® Tablets in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Apr 15 Teva Continues to Invigorate Injectable Portfolio with the Launch of Argatroban Injection in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
27 Apr 15 Teva Reiterates Commitment to Cash-and-Stock Acquisition of Mylan for $82.00 Per Share Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
23 Apr 15 Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS Teva Pharmaceutical Industries Ltd. and Active Biotech,
Published by
Business Wire
23 Apr 15 Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
22 Apr 15 Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 Apr 15 Teva to Report First Quarter 2015 Financial Results on April 30 2015 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
14 Apr 15 Teva and Eagle Pharmaceuticals Announce NDA for Bendamustine Rapid Infusion Product Accepted for Filing Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc.,
Published by
Business Wire
13 Apr 15 Teva to Present Multiple Sclerosis Data at 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Apr 15 Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Apr 15 Teva Announces FDA Approval of ProAir® RespiClick Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 Mar 15 Teva Expands Hypertension Line with Launch of Generic Exforge® Tablets in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
23 Mar 15 Teva Announces New Head of Business Development Strategy and Innovation Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
23 Mar 15 Teva’s TEV-48125 Meets Primary and Secondary Endpoints in Episodic Migraine Study Demonstrating Treatment Concept After a Single Dose Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 Mar 15 Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Mar 15 Teva to Present at the Barclays Global Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Mar 15 Teva Announces Sale of Sellersville PA Facility Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
27 Feb 15 Teva Announces Early Results of Debt Tender Offer Pricing Election of Early Settlement and Increase in Maximum Amount and Priority 2 Notes Tender Cap Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
26 Feb 15 Teva to Present at the Cowen & Company 35th Annual Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Feb 15 Teva and Eagle Pharmaceuticals Announce Teva’s License to Commercialize Eagle’s Bendamustine Rapid Infusion Product Teva Pharmaceutical Industries Ltd.
10 Feb 15 Teva Files 2014 Annual Report on Form 20-F Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Feb 15 Teva Thanks Dr. Phillip Frost for Board Service Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
26 Jan 15 Teva Receives FDA Approval for First Generic Nexium® Delayed-Release Capsules in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
15 Jan 15 Teva to Report Fourth Quarter 2014 Financial Results on February 5 2015 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.